BioMarin Pharmaceutical 1Q 2026: Revenue $766.2M, EPS $0.54— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.BioMarin Pharmaceutical reported Q1 2026 results with revenue of $766.2M, a 2.8% increase from $745.1M a year prior. However, net income fell to $105.5M from $185.7M, and diluted EPS decreased to $0.54 from $0.95. The revenue growth was driven by higher product volumes for VIMIZIM, NAGLAZYME, and VOXZOGO, aided by favorable currency exchange rates. The company completed the Amicus acquisition and enrolled the first patient in the Phase 2/3 BMN 333 study. Gross margin was impacted by a $31M charge related to NAGLAZYME.
BioMarin Pharmaceutical reported first-quarter 2026 results with revenue of $766.2M, up 2.8% from $745.1M a year earlier, while net income fell to $105.5M from $185.7M and diluted EPS declined to $0.54 from $0.95— results filed in the company’s 10-Q.
Financial Highlights
- Revenue was $766.2M for Q1 2026, compared with $745.1M in the year-ago quarter; YoY change 2.8%.
- Net income was $105.5M for Q1 2026, compared with $185.7M in the year-ago quarter; YoY change (43.2%).
- Diluted EPS was $0.54 for Q1 2026, compared with $0.95 in the year-ago quarter.
Business Highlights
- Total revenues rose modestly, driven by higher product volumes for VIMIZIM, NAGLAZYME and VOXZOGO.
- Growth reflected timing of large government orders and new patient initiations across regions; a stronger euro and Mexican peso aided foreign-currency sales.
- Brand momentum included global expansion of VOXZOGO and enzyme therapies and U.S. approval of PALYNZIQ for adolescents.
- Company completed the Amicus acquisition in April 2026, adding GALAFOLD and a Pompe therapy combination, and enrolled the first patient in the Phase 2/3 BMN 333 study.
- Gross margin was pressured by a $31M charge tied to a failed NAGLAZYME process qualification; inventory and campaign timing also affected operating cash flow.
Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 10-Q - May. 05, 2026